Olfactory receptors in neural regeneration in the central nervous system

Olfactory receptors are crucial for detecting odors and play a vital role in our sense of smell,influencing behaviors from food choices to emotional memories.These receptors also contribute to our perception of flavor and have potential applications in medical diagnostics and environmental monitoring.The ability of the olfactory system to regenerate its sensory neurons provides a unique model to study neural regeneration,a phenomenon largely absent in the central nervous system.Insights gained from how olfactory neurons continuously replace themselves and reestablish functional connections can provide strategies to promote similar regenerative processes in the central nervous system,where damage often results in permanent deficits.Understanding the molecular and cellular mechanisms underpinning olfactory neuron regeneration could pave the way for developing therapeutic approaches to treat spinal co rd injuries and neurodegenerative diseases like Alzheimer's disease.Olfa ctory receptors are found in almost any cell of eve ry orga n/tissue of the mammalian body.This ectopic expression provides insights into the chemical structures that can activate olfactory receptors.In addition to odors,olfactory receptors in ectopic expression may respond to endogenous compounds and molecules produced by mucosal colonizing microbiota.The analysis of the function of olfactory receptors in ectopic expression provides valuable information on the signaling pathway engaged upon receptor activation and the receptor's role in proliferation and cell differentiation mechanisms.This review explo res the ectopic expression of olfa ctory receptors and the role they may play in neural regeneration within the central nervous system,with particular attention to compounds that can activate these receptors to initiate regenerative processes.Evidence suggests that olfactory receptors could serve as potential therapeutic targets for enhancing neural repair and recovery following central nervous system injuries.

P2Y1 receptor in Alzheimer’s disease

Alzheimer’s disease is the most frequent form of dementia characterized by the deposition of amyloid-beta plaques and neurofibrillary tangles consisting of hyperphosphorylated tau.Targeting amyloid-beta plaques has been a primary direction for developing Alzheimer’s disease treatments in the last decades.However,existing drugs targeting amyloid-beta plaques have not fully yielded the expected results in the clinic,necessitating the exploration of alternative therapeutic strategies.Increasing evidence unravels that astrocyte morphology and function alter in the brain of Alzheimer’s disease patients,with dysregulated astrocytic purinergic receptors,particularly the P2Y1 receptor,all of which constitute the pathophysiology of Alzheimer’s disease.These receptors are not only crucial for maintaining normal astrocyte function but are also highly implicated in neuroinflammation in Alzheimer’s disease.This review delves into recent insights into the association between P2Y1 receptor and Alzheimer’s disease to underscore the potential neuroprotective role of P2Y1 receptor in Alzheimer’s disease by mitigating neuroinflammation,thus offering promising avenues for developing drugs for Alzheimer’s disease and potentially contributing to the development of more effective treatments.

C-C motif chemokine ligand 2/C-C motif chemokine receptor 2 pathway as a therapeutic target and regulatory mechanism for spinal cord injury

Spinal cord injury involves non-reversible damage to the central nervous system that is characterized by limited regenerative capacity and secondary inflammatory damage.The expression of the C-C motif chemokine ligand 2/C-C motif chemokine receptor 2 axis exhibits significant differences before and after injury.Recent studies have revealed that the C-C motif chemokine ligand 2/C-C motif chemokine receptor 2 axis is closely associated with secondary inflammatory responses and the recruitment of immune cells following spinal cord injury,suggesting that this axis is a novel target and regulatory control point for treatment.This review comprehensively examines the therapeutic strategies targeting the C-C motif chemokine ligand 2/C-C motif chemokine receptor 2 axis,along with the regenerative and repair mechanisms linking the axis to spinal cord injury.Additionally,we summarize the upstream and downstream inflammatory signaling pathways associated with spinal cord injury and the C-C motif chemokine ligand 2/C-C motif chemokine receptor 2 axis.This review primarily elaborates on therapeutic strategies that target the C-C motif chemokine ligand 2/C-C motif chemokine receptor 2 axis and the latest progress of research on antagonistic drugs,along with the approaches used to exploit new therapeutic targets within the C-C motif chemokine ligand 2/C-C motif chemokine receptor 2 axis and the development of targeted drugs.Nevertheless,there are presently no clinical studies relating to spinal cord injury that are focusing on the C-C motif chemokine ligand 2/C-C motif chemokine receptor 2 axis.This review aims to provide new ideas and therapeutic strategies for the future treatment of spinal cord injury.

Hypidone hydrochloride(YL-0919)ameliorates functional deficits after traumatic brain injury in mice by activating the sigma-1 receptor for antioxidation

Traumatic brain injury involves complex pathophysiological mechanisms,among which oxidative stress significantly contributes to the occurrence of secondary injury.In this study,we evaluated hypidone hydrochloride(YL-0919),a self-developed antidepressant with selective sigma-1 receptor agonist properties,and its associated mechanisms and targets in traumatic brain injury.Behavioral experiments to assess functional deficits were followed by assessment of neuronal damage through histological analyses and examination of blood-brain barrier permeability and brain edema.Next,we investigated the antioxidative effects of YL-0919 by assessing the levels of traditional markers of oxidative stress in vivo in mice and in vitro in HT22 cells.Finally,the targeted action of YL-0919 was verified by employing a sigma-1 receptor antagonist(BD-1047).Our findings demonstrated that YL-0919 markedly improved deficits in motor function and spatial cognition on day 3 post traumatic brain injury,while also decreasing neuronal mortality and reversing blood-brain barrier disruption and brain edema.Furthermore,YL-0919 effectively combated oxidative stress both in vivo and in vitro.The protective effects of YL-0919 were partially inhibited by BD-1047.These results indicated that YL-0919 relieved impairments in motor and spatial cognition by restraining oxidative stress,a neuroprotective effect that was partially reversed by the sigma-1 receptor antagonist BD-1047.YL-0919 may have potential as a new treatment for traumatic brain injury.

Glucocorticoid receptor signaling in the brain and its involvement in cognitive function

The hypothalamic-pituitary-adrenal axis regulates the secretion of glucoco rticoids in response to environmental challenges.In the brain,a nuclear receptor transcription fa ctor,the glucocorticoid recepto r,is an important component of the hypothalamicpituitary-a d renal axis's negative feedback loop and plays a key role in regulating cognitive equilibrium and neuroplasticity.The glucoco rticoid receptor influences cognitive processes,including glutamate neurotransmission,calcium signaling,and the activation of brain-derived neurotrophic factor-mediated pathways,through a combination of genomic and non-genomic mechanisms.Protein interactions within the central nervous system can alter the expression and activity of the glucocorticoid receptor,there by affecting the hypothalamic-pituitary-a d renal axis and stress-related cognitive functions.An appropriate level of glucocorticoid receptor expression can improve cognitive function,while excessive glucocorticoid receptors or long-term exposure to glucoco rticoids may lead to cognitive impairment.Patients with cognitive impairment-associated diseases,such as Alzheimer's disease,aging,depression,Parkinson's disease,Huntington's disease,stroke,and addiction,often present with dysregulation of the hypothalamic-pituitary-adrenal axis and glucocorticoid receptor expression.This review provides a comprehensive overview of the functions of the glucoco rticoid receptor in the hypothalamic-pituitary-a d renal axis and cognitive activities.It emphasizes that appropriate glucocorticoid receptor signaling fa cilitates learning and memory,while its dysregulation can lead to cognitive impairment.This provides clues about how glucocorticoid receptor signaling can be targeted to ove rcome cognitive disability-related disorders.

Overexpression of low-density lipoprotein receptor prevents neurotoxic polarization of astrocytes via inhibiting NLRP3 inflammasome activation in experimental ischemic stroke

Neurotoxic astrocytes are a promising therapeutic target for the attenuation of cerebral ischemia/reperfusion injury.Low-density lipoprotein receptor,a classic cholesterol regulatory receptor,has been found to inhibit NLR family pyrin domain containing protein 3(NLRP3)inflammasome activation in neurons following ischemic stroke and to suppress the activation of microglia and astrocytes in individuals with Alzheimer’s disease.However,little is known about the effects of low-density lipoprotein receptor on astrocytic activation in ischemic stroke.To address this issue in the present study,we examined the mechanisms by which low-density lipoprotein receptor regulates astrocytic polarization in ischemic stroke models.First,we examined low-density lipoprotein receptor expression in astrocytes via immunofluorescence staining and western blotting analysis.We observed significant downregulation of low-density lipoprotein receptor following middle cerebral artery occlusion reperfusion and oxygen-glucose deprivation/reoxygenation.Second,we induced the astrocyte-specific overexpression of low-density lipoprotein receptor using astrocyte-specific adeno-associated virus.Low-density lipoprotein receptor overexpression in astrocytes improved neurological outcomes in middle cerebral artery occlusion mice and reversed neurotoxic astrocytes to create a neuroprotective phenotype.Finally,we found that the overexpression of low-density lipoprotein receptor inhibited NLRP3 inflammasome activation in oxygen-glucose deprivation/reoxygenation injured astrocytes and that the addition of nigericin,an NLRP3 agonist,restored the neurotoxic astrocyte phenotype.These findings suggest that low-density lipoprotein receptor could inhibit the NLRP3-meidiated neurotoxic polarization of astrocytes and that increasing low-density lipoprotein receptor in astrocytes might represent a novel strategy for treating cerebral ischemic stroke.

Pan-TRK positive uterine sarcoma in immunohistochemistry without neurotrophic tyrosine receptor kinase gene fusions:A case report

BACKGROUND The classification of uterine sarcomas is based on distinctive morphological and immunophenotypic characteristics,increasingly supported by molecular genetic diagnostics.Data on neurotrophic tyrosine receptor kinase(NTRK)gene fusionpositive uterine sarcoma,potentially aggressive and morphologically similar to fibrosarcoma,are limited due to its recent recognition.Pan-TRK immunohistochemistry(IHC)analysis serves as an effective screening tool with high sensitivity and specificity for NTRK-fusion malignancies.CASE SUMMARY We report a case of a malignant mesenchymal tumor originating from the uterine cervix,which was pan-TRK IHC-positive but lacked NTRK gene fusions,accompanied by a brief literature review.A 55-year-old woman presented to the emergency department with abdominal pain and distension,exhibiting significant ascites and multiple solid pelvic masses.Pelvic examination revealed a tumor encompassing the uterine cervix,extending to the vagina and uterine corpus.A punch biopsy of the cervix indicated NTRK sarcoma with positive immunochemical pan-TRK stain.However,subsequent next generation sequencing revealed no NTRK gene fusion,leading to a diagnosis of poorly differentiated,advanced-stage sarcoma.CONCLUSION The clinical significance of NTRK gene fusion lies in potential treatment with TRK inhibitors for positive sarcomas.Identifying such rare tumors is crucial due to the potential applicability of tropomyosin receptor kinase inhibitor treatment.

Reduced mesencephalic astrocyte-derived neurotrophic factor expression by mutant androgen receptor contributes to neurodegeneration in a model of spinal and bulbar muscular atrophy pathology

Spinal and bulbar muscular atrophy is a neurodegenerative disease caused by extended CAG trinucleotide repeats in the androgen receptor gene,which encodes a ligand-dependent transcription facto r.The mutant androgen receptor protein,characterized by polyglutamine expansion,is prone to misfolding and forms aggregates in both the nucleus and cytoplasm in the brain in spinal and bulbar muscular atrophy patients.These aggregates alter protein-protein interactions and compromise transcriptional activity.In this study,we reported that in both cultured N2a cells and mouse brain,mutant androgen receptor with polyglutamine expansion causes reduced expression of mesencephalic astrocyte-de rived neurotrophic factor.Overexpressio n of mesencephalic astrocyte-derived neurotrophic factor amelio rated the neurotoxicity of mutant androgen receptor through the inhibition of mutant androgen receptor aggregation.Conversely.knocking down endogenous mesencephalic astrocyte-derived neurotrophic factor in the mouse brain exacerbated neuronal damage and mutant androgen receptor aggregation.Our findings suggest that inhibition of mesencephalic astrocyte-derived neurotrophic factor expression by mutant androgen receptor is a potential mechanism underlying neurodegeneration in spinal and bulbar muscular atrophy.

Cortico-striatal gamma oscillations are modulated by dopamine D3 receptors in dyskinetic rats

Long-term levodopa administration can lead to the development of levodopa-induced dyskinesia.Gamma oscillations are a widely recognized hallmark of abnormal neural electrical activity in levodopa-induced dyskinesia.Currently,studies have reported increased oscillation power in cases of levodopa-induced dyskinesia.However,little is known about how the other electrophysiological parameters of gamma oscillations are altered in levodopa-induced dyskinesia.Furthermore,the role of the dopamine D3 receptor,which is implicated in levodopa-induced dyskinesia,in movement disorder-related changes in neural oscillations is unclear.We found that the cortico-striatal functional connectivity of beta oscillations was enhanced in a model of Parkinson’s disease.Furthermore,levodopa application enhanced cortical gamma oscillations in cortico-striatal projections and cortical gamma aperiodic components,as well as bidirectional primary motor cortex(M1)↔dorsolateral striatum gamma flow.Administration of PD128907(a selective dopamine D3 receptor agonist)induced dyskinesia and excessive gamma oscillations with a bidirectional M1↔dorsolateral striatum flow.However,administration of PG01037(a selective dopamine D3 receptor antagonist)attenuated dyskinesia,suppressed gamma oscillations and cortical gamma aperiodic components,and decreased gamma causality in the M1→dorsolateral striatum direction.These findings suggest that the dopamine D3 receptor plays a role in dyskinesia-related oscillatory activity,and that it has potential as a therapeutic target for levodopa-induced dyskinesia.

FC-TBL教学模式在生物制品学课程中的实践研究

生物制品学是以现代生物技术为核心的一门新的独立学科,其研究成果在全球重大、流行性疾病的预防、治疗、诊断中发挥了不可忽视的作用。本研究以培养创新型生物技术人才为目标,在生物制品学课程中开展了以互联网+学习平台为基础的“自主初探+团队协作+师生探讨”相结合的以团队为基础的翻转课堂(flipped classroom and team-based learning,FC-TBL)教学模式,并从教学设计、教学资源平台建设、教学评价体系建立3个方面总结了该教学模式的实践经验,以期为相关教学研究提供参考。

人Fcα/μR和Poly Immunoglobulin Receptor多克隆抗体的制备及鉴定

目的:制备抗人Fcα/μR和Poly Immunoglobulin Receptor(pIgR)的多克隆抗体。方法:在Escherichia coli中分别表达人Fcα/μR的EC12和pIgR的D1结构域,均以包含体形式存在。从SDS-PAGE中切胶纯化,免疫新西兰兔,制备多克隆抗体。ELISA法检测抗体效价,Western blot法检测抗体的特异性,抗原柱吸收交叉和纯化多抗。结果:抗体滴度分别是1∶6 4000和1∶25 6000,经Western blot检测特异性良好,抗人Fcα/μR和pIgR的多抗相互没有交叉。结论:在E.coli中成功表达了人Fcα/μR的EC12结构域和pIgR的D1结构域,并制备了无交叉的多克隆抗体,为进一步研究其功能和相互关系奠定基础。

基于网络药理学探究三七皂苷Ft1和Fc治疗血栓的潜在位点分析

为探讨三七中活性成分三七皂苷Ft1和Fc治疗血栓疾病的作用机制,通过Swiss Target Prediction、Super-pred、BindingDB数据库检索三七Ft1、Fc靶点,在OMIM、Gene Cards、Drug Bank数据库中检索与血栓疾病发生相关靶点,借助Venny网站和STRING数据库建立靶蛋白互作网络模型,使用Centiscape 2.2进行拓扑参数分析,并且对三七Ft1和Fc核心靶点进行GO、KEGG通路富集分析,最后进行分子对接验证。结果表明,三七皂苷Ft1、Fc分别有90和149个预测靶点,4303个与血栓疾病发生相关靶点,维恩图分析核心靶点分别为14和18个,其中三七Ft1与其核心靶点STAT3、VEGFA、HSP90AA1紧密结合,三七Fc与其核心靶点STAT3、VEGFA、CXCR4紧密结合。基于网络药理学,探讨三七皂苷Ft1和Fc治疗血栓多靶点和多途径的特性,为三七皂苷Ft1和Fc治疗血栓疾病的研究提供了新思路。

Distribution of Variant Genotypes of Fc gamma Receptor ⅢA in Healthy Chinese Population of Zhengzhou City

To investigate the distribution of variant genotypes of Fc gamma receptor Ⅲa (FcγRⅢa) in healthy Chinese population of Zhengzhou city, genomic DNA was extracted from peripheral blood of healthy donators The genotypes of FcγRⅢa-158 were determined by nested polymerase chain reaction (PCR) in 137 healthy people in Zhengzhou city The results showed that frequencies of variant genotypes FF, VV and VF were 42 3 %, 48 9 % and 8 8 % respectively The distribution of FcγRⅢa-158 in healthy Chinese population of Zhengzhou city was polymorphic and different from that of African Americans (AA) and Caucasian Americans (CA)

抗体药物Fc段结构域改造研究进展

抗体是生物体内应对外来物质入侵时产生的主要保护物质,是保护生物体的重要分子。对抗体的Fc段进行改造可有效延长抗体的半衰期,大大减少给药剂量;Fc段介导的抗体效应子的功能也可以根据疾病特殊性进行上调或下调,实现治疗效果最大化。同时,仅有Fc片段的抗体,也可具备结合抗原的能力,通过缩小抗体分子的大小,可大大减少抗体分子量大的限制,为抗体药物的开发提供了新的方向。此外,除抗肿瘤作用外,抗体分子在抗感染领域也发挥了重要的作用。对抗感染中和抗体Fc区进行工程改造,可有效促进保护性的细胞免疫效应,增强抗病毒活性并延长半衰期。本文总结了抗体Fc结构域的功能特性及优化策略,并介绍Fc结构域优化改造所介导的生物学效应及在临床治疗中的应用与发展。

Are TrkB receptor agonists the right tool to fulfill the promises for a therapeutic value of the brain-derived neurotrophic factor?

Brain-derived neurotrophic factor signaling via its receptor tro pomyosin receptor kinase B regulates several crucial physiological processes.It has been shown to act in the brain,promoting neuronal survival,growth,and plasticity as well as in the rest of the body where it is involved in regulating for instance aspects of the metabolism.Due to its crucial and very pleiotro pic activity,reduction of brain-derived neurotrophic factor levels and alterations in the brain-derived neurotrophic factor/tropomyosin receptor kinase B signaling have been found to be associated with a wide spectrum of neurological diseases.Howeve r,because of its poor bioavailability and pharmacological properties,brain-derived neurotrophic factor itself has a very low therapeutic value.Moreover,the concomitant binding of exogenous brain-derived neurotrophic factor to the p75 neurotrophin receptor has the potential to elicit several unwanted and deleterious side effects.Therefo re,developing tools and approaches to specifically promote tropomyosin receptor kinase B signaling has become an important goal of translational research.Among the newly developed tools are different categories of tropomyosin receptor kinase B receptor agonist molecules.In this review,we give a comprehensive description of the diffe rent tro pomyosin receptor kinase B receptor agonist drugs developed so far and of the res ults of their application in animal models of several neurological diseases.Moreover,we discuss the main benefits of tropomyosin receptor kinase B receptor agonists,concentrating especially on the new tropomyosin receptor kinase B agonist antibodies.The benefits observed both in vitro and in vivo upon application of tropomyosin receptor kinase B receptor agonist drugs seem to predominantly depend on their general neuroprotective activity and their ability to promote neuronal plasticity.Moreover,tro pomyosin receptor kinase B agonist antibodies have been shown to specifically bind the tropomyosin receptor kinase B receptor and not p75 neurotrophin receptor.Therefore,while,based on the current knowledge,the tropomyosin receptor kinase B receptor agonists do not seem to have the potential to reve rse the disease pathology per se,promoting brainderived neurotrophic factor/tro pomyosin receptor kinase B signaling still has a very high therapeutic relevance.

复方双黄连制剂对单核巨噬细胞(RAW264.7)Fc/C3b受体活性和分泌功能的影响

【目的】探究复方双黄连制剂对巨噬细胞吞噬能力和分泌功能的影响,为复方双黄连的深度开发及畜禽用药的合理选择提供科学依据。【方法】将金银花、黄芩、连翘、穿心莲干燥粉碎后分别制备浸膏,按照比例制备双黄连口服液(金银花∶黄芩∶连翘=1∶1∶2)、复方双黄连口服液(金银花∶黄芩∶连翘∶穿心莲=1∶1∶2∶2)及穿心莲口服液,调节pH为7.0,生药浓度为1 g/mL。3种药物作用于小鼠单核巨噬细胞RAW264.7,采用CCK-8法检测细胞活力,确定3种药物安全浓度,将药物最大安全浓度以二倍稀释法稀释为3个浓度;采用脂多糖(LPS)和氢化考的松琥珀酸钠(HCSS)作用于RAW264.7细胞模拟机体炎症和免疫抑制状态,3种药物作用于这2种状态的细胞和正常细胞,采用YC、EA玫瑰花环法及中性红吞噬法检测巨噬细胞Fc/C3b受体活性和吞噬能力,采用ELISA法检测巨噬细胞分泌能力。【结果】复方双黄连、双黄连、穿心莲的安全浓度分别为0.625~2.5、3.125~12.5和0.625~2.5 mg/mL。不同浓度复方双黄连、双黄连、穿心莲作用于巨噬细胞,细胞吞噬能力均显著高于空白对照组(P<0.05)。复方双黄连可降低LPS巨噬细胞RAW264.7活跃的吞噬能力,增强HCSS巨噬细胞RAW264.7吞噬能力;不同浓度复方双黄连可使活化的巨噬细胞Fc/C3b受体活性下降,低下的Fc/C3b受体活性增强;不同浓度复方双黄连具有促进巨噬细胞分泌一氧化氮(NO)、肿瘤坏死因子-α(TNF-α)、γ-干扰素(IFN-γ)及溶菌酶(LZM)的作用,抑制LPS巨噬细胞NO、TNF-α、IFN-γ及白细胞介素-6(IL-6)的分泌。【结论】复方双黄连可通过活化巨噬细胞Fc/C3b受体活性以增强机体免疫力和抗炎能力,同时对已活化的巨噬细胞分泌功能起到抑制作用,以减少由于免疫功能亢进造成的机体损伤。研究结果为中兽药复方双黄连的深度开发提供了参考依据。

新生儿Fc受体及其抑制剂在原发免疫性血小板减少症中的研究进展

原发免疫性血小板减少症(ITP)是一种由血小板自身抗体介导的自身免疫性疾病,大多数ITP患者具有免疫球蛋白G(IgG)亚型的抗血小板抗体,其通过与血小板和巨核细胞上糖蛋白的相互作用导致血小板破坏增加和抑制血小板的生成。新生儿Fc受体(FcRn)用于维持人体内IgG水平稳态。通过FcRn抑制剂靶向FcRn可以降低血液中的致病性IgG,证明了其对治疗ITP和其他自身免疫性疾病有效,并在一定程度上可改善ITP患者的血小板计数。efgartigimod、Rozanolixizumab均可与FcRn结合进而导致循环IgG减少。FcRn抑制剂还能间接延长罗米司亭的半衰期以提高治疗效果。本综述简要总结了ITP中血小板的破坏和生成抑制机制、FcRn和FcRn抑制剂作用的分子机制、FcRn抑制剂在ITP中的应用以及FcRn与罗米司亭、静脉注射Ig的联系。

THE EFFECT OF FCγ RECEPTOR ON THE PATHOGENESIS OF GRAVES' DISEASE

Objective To explore the roles of Fcγ recep tor in the pathogenesis of Graves' disease. Methods Fcγ receptor gene knockout mice(Fcγ R KO m ice) which were rooted in C57BL/6 mice and wild type C57BL/6 mice were immunized by hTSH receptor expressing cells (DAP3.WT). 1-2×107 DAP3.WT cells were peri toneally injected into mice every two weeks for a total of six times. Two weeks after final immunization, mice were killed for measurement of total thyroxine, T RAb and pathological examination. Results The thyroxine level of the immunized Fcγ recept or gene knockout mice was significantly lower than that of the immunized wild ty pe control mice (2.2±0.31 vs. 3.32± 0.59 g·dL -1, P< 0.05 ),but there was no significant difference between immunized Fcγ R KO mic e and non-immunized wild type control group. The TRAb levels of the immunized F γ R KO mice significantly increased compared to those of the immunized wild type mice (21.75±8.21 vs. 14.11±6.21, P< 0.05). The lymphocyte cel ls infiltration and destruction of thyroid follicles were found in the thyroid gland of the immunized Fcγ R KO mice. Conclusion These results suggest that Fcγ receptor may be involved in the pathogenesis of Graves' disease.

Neuronal Fc gamma receptor I as a novel mediator for IgG immune complex-induced peripheral sensitization

Chronic pain often accompanies immune-related diseases with an elevated level of IgG immune complex （IgG-IC） in the serum and/or the affected tissues though the underlying mechanisms are largely unknown. Fc gamma receptors （FcyRs）, known as the receptors for the Fc domain of immunoglobulin G （IgG）, are typically expressed on immune cells. A general consensus is that the activation of FcyRs by IgG-IC in such immune cells induces the release of proinflammatory cytokines from the immune cells, which may contribute to the IgG-IC-mediated peripheral sensitization. In addition to the immune cells, recent studies have revealed that FcyRI, but not FcyRII and FcyRIII, is also expressed in a subpopulation of primary sensory neurons. Moreover, IgG-IC directly excites the primary sensory neurons through neuronal FcyRI. These findings indicate that neuronal FcyRI provides a novel direct linkage between immunoglobulin and primary sensory neurons, which may be a novel target for the treatment of pain in the immune-related disorders. In this review, we summarize the expression pattern, functions, and the associated cellular signaling of FcyRs in the primary sensory neurons.

BDNF dependent Rac1 GTPase activation in the vmPFC contributes to aversive memory extinction by Arc-mediated GABAA receptor endocytosis

Extinction of aversive memories has been a major concern in neuropsychiatric disorders such as anxiety disorders and drug addiction. The ventromedial prefrontal cortex(vmPFC) is important for memory extinction,but the underlying mechanisms are little known. Here,we report that extinction of conditioned place aversion(CPA),a type of aversive memory associated with drug withdrawal,required activation of Rho GTPase Rac1 in the vmPFC in a brain-derived neurotrophic factor(BDNF)-dependent manner,which triggers actin polymerization via Pak1-cofilin signaling pathway,leading to synaptic localization of activity-regulated cytoskeleton-associated protein(Arc) in the vmPFC. The synaptic Arc further determines GABA_Areceptor(GABA_AR) endocytosis that is necessary and sufficient for vmP FC long-term potentiation and CPA extinction. Thus,extinction of an aversive memory associated with drug withdrawal is intriguingly controlled by Rac1-dependent GABA_AR endocytosis in the vmPFC,thereby suggesting therapeutic targets to promote extinction of the unwanted memory.